<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We used direct sequence analysis to determine if the JAK2V617F mutation was present in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>)/atypical <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (aCML), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), B-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), T-cell ALL, and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of 222 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> identified JAK2V617F mutations in 4 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 3 of whom had a preceding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a <z:mp ids='MP_0005481'>CML</z:mp> samples, and in 2 (4.2%) of 48 MDS samples </plain></SENT>
<SENT sid="5" pm="."><plain>We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45) </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that the JAK2V617F allele is present in <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> but not in lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>